We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Gestalt Diagnostics

Gestalt Diagnostics provides enterprise solutions and services to transform anatomic pathology laboratories from glas... read more Featured Products: More products

Download Mobile App




New AI Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models

By LabMedica International staff writers
Posted on 04 Oct 2023

A new artificial intelligence (AI) algorithm for use on one of the broadest trained environments is now available for commercial or research work. More...

Gestalt Diagnostics (Spokane, WA, USA) has released the Mitotic Counting algorithm which has been trained on more than 100,000 individual mitosis and across seven scanner models. The algorithm performs impressively with an F1-Score of 0.74, matching the performance of top-of-the-line methods in the field. The algorithm is currently available in the Gestalt AI Studio for use on a variety of cancers including cutaneous mast cell tumors, breast cancer, lymphoma, lung cancer, melanoma, neuroendocrine, colon cancer, and bladder carcinoma. The algorithm has been trained on several scanner models, including those from Hamamatsu, Leica, 3D Histech, and Aperio.

Key to the broad applicability of deep learning algorithms is their ability to adapt to new scanners and different types of tissue; a broad dataset is crucial to achieve this goal. Gestalt Diagnostics' dataset encompasses seven types of tissues spanning eight tumors and is digitized with seven different scanner models. Additionally, Gestalt Diagnostics also offers PathFlow, a smart and customizable workflow solution that offers genuine interoperability for optimal efficiency. This solution supports both digital and glass slides and allows for tailored rules that can be can be configured to meet specific needs and requirements.

"What does this mean for our customers? Confidence,” said Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer. “Gestalt is focused on providing solutions that provide a foundation of confidence in use as this industry continues to evolve, innovate, and incorporate products that are meant to enhance a pathologist's or scientist's daily life."

"We are extremely proud of the comprehensive approach we take to AI development as an organization,” added Brian Napora, Gestalt VP, AI Solutions. “Our position is to not only look at development and training with a small subset of images or on one or two scanners, that would not prove as effective or accurate as we feel our customers and the industry require. Therefore, we train on tens of thousands images, tumors cells, or in this case, mitosis and multiple scanner models across several scanner vendors to ensure the most accurate, clinically usable options for our customers."

Related Links:
Gestalt Diagnostics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Automated Urinalysis Solution
UN-9000
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.